1 Tex. Admin. Code § 354.1923 - Review and Evaluation
(a) The Health
and Human Services Commission (Commission) reviews Certifications of
Information to determine the need for a drug to be added to the Texas Drug Code
Index and to determine the need for restrictions, when appropriate. In
determining need, the Commission considers the following:
(1) expansion of the prescriber's
armamentarium by a new drug entity or an additional multiple source
drug;
(2) the predominant use of
the drug in an outpatient setting;
(3) the cost of the drug to pharmacies
compared to:
(A) relevant costs as published
in price reporting compendia;
(B)
the drug company's prices for the drug in other packaging sizes;
(C) the Average Manufacturer Price (AMP) as
defined by
42 U.S.C.
1396r-8(k), as amended;
and
(D) other generically
equivalent drug products; and
(4) whether the drug is part of a category
that is subject to inclusion in a preferred drug list (PDL) under §
354.1924 of this division (relating to Preferred Drug List). If a drug is
subject to inclusion in the PDL, the manufacturer or labeler's provision of
supplemental rebates will be considered when determining whether the product is
subject to prior authorization.
(b) The Commission may return a Certification
of Information for any of the following reasons:
(1) discovery of false, erroneous, or
incomplete information or documentation in the Certification of
Information;
(2) failure of the
drug company to provide the Commission with documentation of the:
(A) approved New Drug Application or
Abbreviated New Drug Application, if applicable; or
(B) Food and Drug Administration (FDA)
approval for marketing;
(3) failure of the drug company to provide
the Commission with the National Drug Code, as defined by and filed with the
FDA, for the drug product as shown on the drug product container sold to the
pharmacy; or
(4) failure of the
drug company to provide the Commission with current prices for the pricing
points on the Certification of Information.
(c) The Commission may deny a request if it
determines that the drug is included in one or more of the following classes:
(1) amphetamines, when used for weight loss,
and obesity control drugs;
(2)
appliances;
(3)
cosmetics;
(4) DESI-ineffective
products;
(5) diagnostic
aids;
(6) durable medical equipment
(rental or purchase);
(7) elastic
stockings;
(8) experimental
drugs;
(9) fertility
drugs;
(10) first aid
supplies;
(11) immunizing
agents;
(12) irrigating
sets;
(13) IV sets;
(14) medical devices;
(15) medical supplies;
(16) oxygen;
(17) products unsuitable for use outside of
physician offices or health care facilities;
(18) shampoos, unless medicated for parasite
control;
(19) skin lotions and
creams (nonlegend cosmetic types);
(20) soaps and soap substitutes;
(21) supports and suspensories;
(22) syringes and needles;
(23) unit-dose or convenience
packaging;
(24) vitamin and
antianemia combinations;
(25)
medical foods; and/or
(26)
nutritional supplements.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.